--(BUSINESS WIRE)--
WHAT: | Pfizer Oncology will host a journalist briefing at the American |
| Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, | |
| June 1, 2008, highlighting key data presentations from a variety | |
| of compounds in several difficult-to-treat tumor types, | |
| including renal cell carcinoma and non-small cell lung cancer. | |
| Leading oncology physicians and researchers will present study | |
| results and offer their professional perspective. | |
WHO: | Robert Figlin, M.D., F.A.C.P., City of Hope |
| Abstract #5024: "Overall survival with sunitinib versus | |
| interferon (IFN)-alfa as first-line treatment of metastatic | |
| renal cell carcinoma (mRCC)" | |
Antonio Gualberto, M.D., Ph.D., Pfizer Global Research and | |
Development | |
| Abstract #10501: "Safety, pharmacokinetics and preliminary | |
| activity of the anti-IGF-1R antibody CP-751,871 in | |
| sarcoma patients" | |
Daniel Karp, M.D., M.D. Anderson Cancer Center | |
| Abstract #8000: "Characterization of NSCLC patients responding | |
| to anti-IGF-1R therapy" | |
Pasi A. Janne, M.D., Ph.D., Dana-Farber Cancer Institute | |
| Abstract #8027, Poster #8: "Preliminary activity and safety | |
| results from a phase I clinical trial of PF-00299804, an | |
| irreversible pan-HER inhibitor, in patients (pts) with NSCLC" | |
John H. Sampson, M.D., Ph.D., Duke University Medical Center | |
| Abstract #2061: "Effect of EGFRvIII-targeted vaccine (CDX-110) | |
| on immune response and TTP when given with simultaneous standard | |
| and continuous temozolomide in patients with GBM" | |
WHEN: | Sunday, June 1, 2008 at 6:00 PM (CT) |
WHERE: | Westin River North - Grand Ballroom A&B |
| 320 N. Dearborn Avenue | |
| Chicago, IL 60610 | |
(312) 744-1900 | |